Corticotropin-releasing hormone improves survival in pneumococcal pneumonia by reducing pulmonary inflammation

Brittney Burnley, Harlan P. Jones

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The use of glucocorticoids to reduce inflammatory responses is largely based on the knowledge of the physiological action of the endogenous glucocorticoid, cortisol. Corticotropin-releasing hormone (CRH) is a neuropeptide released from the hypothalamic–pituitary–adrenal axis of the central nervous system. This hormone serves as an important mediator of adaptive physiological responses to stress. In addition to its role in inducing downstream cortisol release that in turn regulates immune suppression, CRH has also been found to mediate inflammatory responses in peripheral tissues. Streptococcus pneumoniae is a microorganism commonly present among the commensal microflora along the upper respiratory tract. Transmission of disease stems from the resident asymptomatic pneumococcus along the nasal passages. Glucocorticoids are central mediators of immune suppression and are the primary adjuvant pharmacological treatment used to reduce inflammatory responses in patients with severe bacterial pneumonia. However, controversy exists in the effectiveness of glucocorticoid treatment in reducing mortality rates during S. pneumoniae infection. In this study, we compared the effect of the currently utilized pharmacologic glucocorticoid dexamethasone with CRH. Our results demonstrated that intranasal administration of CRH increases survival associated with a decrease in inflammatory cellular immune responses compared to dexamethasone independent of neutrophils. Thus, providing evidence of its use in the management of immune and inflammatory responses brought on by severe pneumococcal infection that could reduce mortality risks.

Original languageEnglish
Article numbere13000
JournalPhysiological Reports
Volume5
Issue number1
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Pneumococcal Pneumonia
Corticotropin-Releasing Hormone
Glucocorticoids
Pneumonia
Survival
Streptococcus pneumoniae
Dexamethasone
Hydrocortisone
Pneumococcal Infections
Bacterial Pneumonia
Intranasal Administration
Physiological Stress
Mortality
Neuropeptides
Nose
Cellular Immunity
Respiratory System
Neutrophils
Central Nervous System
Hormones

Keywords

  • Corticotropin-releasing hormone
  • Streptococcus pneumoniae
  • glucocorticoids
  • inflammation
  • neuropeptides

Cite this

@article{fd16b186fc0a40b092cc6c630bfbc9e9,
title = "Corticotropin-releasing hormone improves survival in pneumococcal pneumonia by reducing pulmonary inflammation",
abstract = "The use of glucocorticoids to reduce inflammatory responses is largely based on the knowledge of the physiological action of the endogenous glucocorticoid, cortisol. Corticotropin-releasing hormone (CRH) is a neuropeptide released from the hypothalamic–pituitary–adrenal axis of the central nervous system. This hormone serves as an important mediator of adaptive physiological responses to stress. In addition to its role in inducing downstream cortisol release that in turn regulates immune suppression, CRH has also been found to mediate inflammatory responses in peripheral tissues. Streptococcus pneumoniae is a microorganism commonly present among the commensal microflora along the upper respiratory tract. Transmission of disease stems from the resident asymptomatic pneumococcus along the nasal passages. Glucocorticoids are central mediators of immune suppression and are the primary adjuvant pharmacological treatment used to reduce inflammatory responses in patients with severe bacterial pneumonia. However, controversy exists in the effectiveness of glucocorticoid treatment in reducing mortality rates during S. pneumoniae infection. In this study, we compared the effect of the currently utilized pharmacologic glucocorticoid dexamethasone with CRH. Our results demonstrated that intranasal administration of CRH increases survival associated with a decrease in inflammatory cellular immune responses compared to dexamethasone independent of neutrophils. Thus, providing evidence of its use in the management of immune and inflammatory responses brought on by severe pneumococcal infection that could reduce mortality risks.",
keywords = "Corticotropin-releasing hormone, Streptococcus pneumoniae, glucocorticoids, inflammation, neuropeptides",
author = "Brittney Burnley and {P. Jones}, Harlan",
year = "2017",
month = "1",
day = "1",
doi = "10.14814/phy2.13000",
language = "English",
volume = "5",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Corticotropin-releasing hormone improves survival in pneumococcal pneumonia by reducing pulmonary inflammation. / Burnley, Brittney; P. Jones, Harlan.

In: Physiological Reports, Vol. 5, No. 1, e13000, 01.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Corticotropin-releasing hormone improves survival in pneumococcal pneumonia by reducing pulmonary inflammation

AU - Burnley, Brittney

AU - P. Jones, Harlan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The use of glucocorticoids to reduce inflammatory responses is largely based on the knowledge of the physiological action of the endogenous glucocorticoid, cortisol. Corticotropin-releasing hormone (CRH) is a neuropeptide released from the hypothalamic–pituitary–adrenal axis of the central nervous system. This hormone serves as an important mediator of adaptive physiological responses to stress. In addition to its role in inducing downstream cortisol release that in turn regulates immune suppression, CRH has also been found to mediate inflammatory responses in peripheral tissues. Streptococcus pneumoniae is a microorganism commonly present among the commensal microflora along the upper respiratory tract. Transmission of disease stems from the resident asymptomatic pneumococcus along the nasal passages. Glucocorticoids are central mediators of immune suppression and are the primary adjuvant pharmacological treatment used to reduce inflammatory responses in patients with severe bacterial pneumonia. However, controversy exists in the effectiveness of glucocorticoid treatment in reducing mortality rates during S. pneumoniae infection. In this study, we compared the effect of the currently utilized pharmacologic glucocorticoid dexamethasone with CRH. Our results demonstrated that intranasal administration of CRH increases survival associated with a decrease in inflammatory cellular immune responses compared to dexamethasone independent of neutrophils. Thus, providing evidence of its use in the management of immune and inflammatory responses brought on by severe pneumococcal infection that could reduce mortality risks.

AB - The use of glucocorticoids to reduce inflammatory responses is largely based on the knowledge of the physiological action of the endogenous glucocorticoid, cortisol. Corticotropin-releasing hormone (CRH) is a neuropeptide released from the hypothalamic–pituitary–adrenal axis of the central nervous system. This hormone serves as an important mediator of adaptive physiological responses to stress. In addition to its role in inducing downstream cortisol release that in turn regulates immune suppression, CRH has also been found to mediate inflammatory responses in peripheral tissues. Streptococcus pneumoniae is a microorganism commonly present among the commensal microflora along the upper respiratory tract. Transmission of disease stems from the resident asymptomatic pneumococcus along the nasal passages. Glucocorticoids are central mediators of immune suppression and are the primary adjuvant pharmacological treatment used to reduce inflammatory responses in patients with severe bacterial pneumonia. However, controversy exists in the effectiveness of glucocorticoid treatment in reducing mortality rates during S. pneumoniae infection. In this study, we compared the effect of the currently utilized pharmacologic glucocorticoid dexamethasone with CRH. Our results demonstrated that intranasal administration of CRH increases survival associated with a decrease in inflammatory cellular immune responses compared to dexamethasone independent of neutrophils. Thus, providing evidence of its use in the management of immune and inflammatory responses brought on by severe pneumococcal infection that could reduce mortality risks.

KW - Corticotropin-releasing hormone

KW - Streptococcus pneumoniae

KW - glucocorticoids

KW - inflammation

KW - neuropeptides

UR - http://www.scopus.com/inward/record.url?scp=85009201747&partnerID=8YFLogxK

U2 - 10.14814/phy2.13000

DO - 10.14814/phy2.13000

M3 - Article

C2 - 28057851

AN - SCOPUS:85009201747

VL - 5

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 1

M1 - e13000

ER -